13F Holdings
中文EN

XERS Xeris Biopharma Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1867096 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY38.4%
TTM net income YoY58.5%
TTM EPS YoY70.0%
Revenue 3-yr CAGR34.1%
Net income 3-yr CAGR—

Margins

Gross margin87.4%
Operating margin12.7%
Net margin-1.8%
FCF margin—
EBITDA margin13.1%

Returns

ROE-27.1%
ROA-1.6%
ROIC (approx.)31.5%
Asset turnover0.93x

Leverage & solvency

Liabilities / assets88.5%
Debt / equity3.89x
Current ratio2.15x
Interest coverage1.70x

Cash quality & payout

Operating cash flow / net income-11.34x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$291.85M$203.07M$163.91M$110.25M$49.59M
Cost of revenue$42.57M$36.83M$28.64M$22.63M$13.32M
Gross profit$249.28M$166.24M$135.27M$87.61M$36.27M
R&D expense$31.16M$25.56M$22.34M$20.97M$25.16M
SG&A expense$182.37M$163.48M$146.09M$137.75M$125.72M
Operating income$24.90M-$33.65M-$44.01M-$81.94M-$115.16M
Interest expense$29.08M$30.48M$26.61M$14.10M$7.18M
Pretax income$554,000-$57.10M-$63.50M-$96.08M-$122.72M
Income tax$0-$2.27M-$1.25M-$1.42M$0
Net income$554,000-$54.84M-$62.26M-$94.66M-$122.72M
EBITDA$26.21M-$32.42M-$42.52M-$80.54M-$113.83M
EPS (basic)0.00-0.37-0.45-0.70-1.55
EPS (diluted)0.00-0.37-0.45-0.70-1.55
Weighted avg. shares (diluted)172.74M146.77M137.67M135.63M79.03M
Balance sheet
Cash & equivalents$111.04M$75.74M$67.45M$126.31M$67.27M
Short-term investments—$0$5.00M$0$35.16M
Receivables$51.05M$40.41M$39.20M$30.83M$17.46M
Inventory$68.67M$48.17M$38.84M$24.73M$18.12M
Current assets$240.31M$167.66M$156.26M$186.82M$142.60M
PP&E, net$4.95M$5.56M$5.97M$5.52M$6.63M
Goodwill$22.86M$22.86M$22.86M$22.86M$22.86M
Intangibles$88.08M$98.92M$109.76M$120.61M$131.45M
Total assets$383.53M$323.06M$322.60M$344.52M$304.36M
Current liabilities$109.57M$100.44M$95.19M$73.62M$79.04M
Short-term debt$0$15.10M$0——
Long-term debt$220.34M$217.01M$190.93M$187.07M$88.07M
Total debt$220.34M$232.11M$190.93M$187.07M$88.07M
Total liabilities$369.84M$352.68M$329.38M$299.33M$209.13M
Shareholders' equity$13.69M-$29.61M-$6.78M$45.19M$95.23M
Net debt$109.29M$156.36M$123.48M$60.76M$20.80M
Shares outstanding166.22M149.43M138.13M136.27M124.87M
Cash flow statement
Operating cash flow$28.63M-$36.98M-$47.02M-$102.89M-$95.53M
Capital expenditure————$1.08M
Free cash flow————-$96.62M
Investing cash flow-$696,000$4.88M-$6.00M$34.46M$97.96M
Financing cash flow$11.39M$36.17M-$1.61M$127.47M$27.25M
Depreciation & amortization$1.31M$1.23M$1.49M$1.40M$1.33M
Stock-based compensation$22.37M$18.36M$10.72M$12.16M$11.38M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.